依达拉奉治疗急性脑梗死53例疗效观察

目的观察氧自由基清除剂-依达拉奉治疗急性脑梗死（ACI）的疗效。方法采用随机对照试验,选择发病24h内的ACI患者100例,随机分为治疗组（53例）及对照组（47例）。对照组用血塞通注射液＋肠溶阿司匹林,治疗组在常规治疗的基础上加用依达拉奉30mg,每日2次,静脉滴注,疗程均为两周（14d）。治疗前后定期对患者进行神经功能缺损评定,日常生活活动能力（ADL）评定,神经功能缺损评定采用中国卒中量表（CSS）,ADL评定采用Barthel指数量表,以治疗第21dCSS和ADL改变作为主要疗效判断标准。结果治疗组总有效率为84.9%,对照组总有效率为68.1%;21d后治疗组、对照组CSS、ADL相比差异有显著性（P〈0.05）,两组无明显不良反应。结论依达拉奉能有效改善急性脑梗死的神经功能缺失和日常生活活动能力,无明显不良反应。依达拉奉治疗ACI患者疗效好,安全性高,值得临床推广应用。

Clinical observation on efficacy of Edaravone in treatment of 53 patients with acute cerebral infarction

Objective To evaluate the efficacy and adverse reactions of Edaravone in treatment of acute cerebral infarction（ACI）.Methods A randomized controlled study was carried out in treatment of 100 patients with ACI enrolled within 24 hours of onset,they were randomly allocated into treatment group（n =53）and control group（n =47）.Patients in both groups were given Xuesaitong Injection and aspirin 50～75 mg orally once per day.Patients in treatment group also received Edaravone injection 30 mg twice per day for 14 days.The neurological deficits and activities of daily living（ADL）of patients in both groups were assessed by using Chinese Stroke Scale（CSS）and Barthel Index respectively before and after the treatment.Clinical efficacy was evaluated according to changes of CSS and ADL scores on the 21th day.Results The efficacy rates in treatment group and control group were 84.9% and 68.1% respectively（P〈0.05）.There was a significant difference in CSS scores and ADL scores between treatment group and control group（P〈0.05）.There was no distinct adverse reaction seen in these two groups.Conclusion Edaravone can improve impaired neurological function and activities of daily living in patients with acute cerebral infarction without obviously adverse reaction.Edaravone is effective and safe in treatment of patients with acute cerebral infarction.It is worthy to be recommended for clinical application.